Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis

Primary biliary cirrhosis is a chronic, progressive, cholestatic liver disease thought to be related to abnormalities in immune regulation. The disease is associated with granulomatous bile duct destruction, cholestasis, hepatic copper overloading and the development of hepatic fibrosis or cirrhosis or both. There have been numerous therapeutic trials evaluating immunosuppres‐sive, antifibrotic and cupruretic agents. Prednisolone, D‐penicillamine, azathioprine, colchicine and chloram‐bucil have been evaluated in controlled clinical trials, and biochemical improvement of liver function has been noted with all of the agents, except D‐penicillamine. Improved survival has also been reported in patients treated long‐term with azathioprine and colchicine. However, none of the therapeutic agents has been demonstrated to halt histologic progression of the disease or to induce a complete clinical, biochemical and histologic remission as has been reported in patients with autoimmune chronic active hepatitis treated with corticoste‐roids. Many of the trials did not use a double‐blind design, failed to use the “intent to treat” rule or failed to define an objective time to analyze results. Many of the studies involved small numbers of patients with short‐term follow‐up and thus potentially were inadequate to appreciate drug effects that might be of clinical benefit. Currently, there is no totally effective therapy for primary biliary cirrhosis. We believe that well‐designed clinical trials can provide important information to better understand this disease until a totally effective therapy is available. New clinical trials should use well‐established methodologic guidelines in study design and well‐accepted statistical standards in the analysis and interpretation of results.

[1]  B. Taal,et al.  Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis. , 2008, Liver.

[2]  Y. Chrétien,et al.  IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS? , 1987, The Lancet.

[3]  Stephen L. George,et al.  Fundamentals of Clinical Trials. (2nd ed.). , 1987 .

[4]  C. Mulrow.  The medical review article: state of the science. , 1987, Annals of internal medicine.

[5]  M. Kaplan,et al.  A prospective trial of colchicine for primary biliary cirrhosis. , 1986, The New England journal of medicine.

[6]  J. Hoofnagle,et al.  Randomized trial of chlorambucil for primary biliary cirrhosis. , 1986, Gastroenterology.

[7]  M. Bennett,et al.  Positive antimitochondrial antibody but normal alkaline phosphatase: Is this primary biliary cirrhosis? , 1986, Hepatology.

[8]  F. Klion,et al.  A prospective clinical trial of D‐penicillamine in the treatment of primary biliary cirrhosis , 1985, Hepatology.

[9]  D. Altman,et al.  Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. , 1985, Gastroenterology.

[10]  J. Neuberger,et al.  In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis. , 1985, Clinical and experimental immunology.

[11]  J. Boyer,et al.  Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. , 1985, Gastroenterology.

[12]  J. Neuberger,et al.  Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. , 1985, Gastroenterology.

[13]  T R Fleming,et al.  Trial of penicillamine in advanced primary biliary cirrhosis. , 1985, The New England journal of medicine.

[14]  S. Lindgren,et al.  Complement activation in primary biliary cirrhosis: an in vitro model. , 1985, The Journal of laboratory and clinical medicine.

[15]  N Tygstrup,et al.  Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. , 1985, Gut.

[16]  M. Ananthanarayanan,et al.  Immunological characterization of the hepatocyte bile acid transport system , 1984 .

[17]  D. Doniach,et al.  ABERRANT EXPRESSION OF HLA-DR ANTIGENS ON BILEDUCT EPITHELIUM IN PRIMARY BILIARY CIRRHOSIS: RELEVANCE TO PATHOGENESIS , 1984, The Lancet.

[18]  G. Delpré,et al.  In vitro correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine. , 1984, Clinical and experimental immunology.

[19]  J. Neuberger,et al.  Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. , 1984, Clinical and experimental immunology.

[20]  J. Hoofnagle,et al.  Primary Biliary Cirrhosis: A Model Autoimmune Disease , 1983 .

[21]  D. Schoenfeld,et al.  Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.

[22]  E. Bauer,et al.  Colchicine-induced modulation of collagenase in human skin fibroblast cultures. I. Stimulation of enzyme synthesis in normal cells. , 1982, The Journal of investigative dermatology.

[23]  D. Ilfeld,et al.  Correction of a suppressor cell deficiency in four patients with familial Mediterranean fever by in vitro or in vivo colchicine. , 1982, Clinical and experimental immunology.

[24]  V. Pinn,et al.  Evidence against an immune complex pathogenesis of primary biliary cirrhosis. , 1982, Gastroenterology.

[25]  E. Dickson,et al.  Autoimmune associations in primary biliary cirrhosis. , 1982, Mayo Clinic proceedings.

[26]  S. Lindgren,et al.  IgM in primary biliary cirrhosis. Physicochemical and complement activating properties. , 1982, The Journal of laboratory and clinical medicine.

[27]  M. Kaplan,et al.  A prospective trial of D-penicillamine in primary biliary cirrhosis. , 1982, The New England journal of medicine.

[28]  E. Reinherz,et al.  Alterations of T-cell subsets in primary biliary cirrhosis. , 1982, Clinical and experimental immunology.

[29]  C. Gisselbrecht,et al.  Ultrastructural lesions of bile ducts in primary biliary cirrhosis. A comparison with the lesions observed in graft versus host disease. , 1981, Human pathology.

[30]  S. Sherlock,et al.  D-PENICILLAMINE TREATMENT IMPROVES SURVIVAL IN PRIMARY BILIARY CIRRHOSIS , 1981, The Lancet.

[31]  J. Lachin.  Introduction to sample size determination and power analysis for clinical trials. , 1981, Controlled clinical trials.

[32]  J. Goldberg,et al.  Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. , 1981, The New England journal of medicine.

[33]  C. Elson,et al.  Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis. , 1980, The Journal of clinical investigation.

[34]  C. Elson,et al.  Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis , 1980 .

[35]  E. Christensen,et al.  Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. , 1980, Gastroenterology.

[36]  P. Lipsky,et al.  Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4. , 1980, The Journal of clinical investigation.

[37]  E. Christensen,et al.  Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. , 1980, Gastroenterology.

[38]  J. Ingelfinger,et al.  Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. , 1980, The New England journal of medicine.

[39]  D. Kershenobich,et al.  Treatment of cirrhosis with colchicine. A double-blind randomized trial. , 1979, Gastroenterology.

[40]  F. Rosner,et al.  Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases. , 1979, Archives of internal medicine.

[41]  S. Sherlock,et al.  Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. , 1979, The New England journal of medicine.

[42]  E. Dickson,et al.  Circulating IgG complexes in primary biliary cirrhosis. A serial study in forty patients followed for two years. , 1978, Clinical and experimental immunology.

[43]  K. Isselbacher,et al.  Circulating immune complexes and complement activation in primary biliary cirrhosis. , 1978, The New England journal of medicine.

[44]  S. Roath,et al.  D-PENICILLAMINE IN PRIMARY BILIARY CIRRHOSIS , 1977, The Lancet.

[45]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[46]  R. Galbraith,et al.  Rheumatic disorders in primary biliary cirrhosis. , 1976, Annals of the rheumatic diseases.

[47]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[48]  E. Elias,et al.  Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis. , 1976, The Journal of laboratory and clinical medicine.

[49]  S. Sherlock,et al.  A prospective controlled trial of azathioprine in primary biliary cirrhosis. , 1976, Gastroenterology.

[50]  S. Malawista,et al.  The action of colchicine in acute gouty arthritis. , 1975, Arthritis and rheumatism.

[51]  D. Mills,et al.  STARCH EMBOLI IN TRANSPLANTED KIDNEYS , 1974 .

[52]  L. Elveback,et al.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. , 1972, Gastroenterology.

[53]  R. Diegelmann,et al.  Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Lynch,et al.  Long-term therapy of Wilson's disease. , 1971, Annals of internal medicine.

[55]  M. Nimni,et al.  Collagen defect induced by penicillamine. , 1965, Science.

[56]  I. Sternlieb,et al.  PENICILLAMINE THERAPY FOR HEPATOLENTICULAR DEGENERATION. , 1964, JAMA.

[57]  J. Giansiracusa,et al.  Effect of steroid therapy on the clinical and laboratory features of primary biliary cirrhosis. , 1955, Gastroenterology.

[58]  I. Mcfarlane.  Autoreactivity against biliary tract antigens in primary biliary cirrhosis. , 1985, Molecular aspects of medicine.

[59]  S. Lindgren,et al.  Complement Components and Activation in Primary Biliary Cirrhosis , 1984, Hepatology.

[60]  C. Elson,et al.  Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis. , 1980, Gastroenterology.

[61]  H. T. Howat,et al.  The late results of long-term treatment of primary biliary cirrhosis by corticosteroids. , 1966, Revue internationale d'hepatologie.